RPS9

Small ribosomal subunit protein uS4 · P46781 · RPS9 on Sugi Atlas →

3,663 patent compounds predicted against RPS9, 1,920 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL5500526	0.41	4/20
SCHEMBL5500532	0.41	4/20
SCHEMBL5503310	0.41	4/20
SCHEMBL11844361	0.35	4/20
SCHEMBL2000440	0.39	3/20
SCHEMBL8219903	0.36	3/20
SCHEMBL11627320	0.34	3/20
SCHEMBL10271044	0.55	2/20
SCHEMBL6394396	0.47	2/20
N-Methylpiperidine (SCHEMBL11205373)	0.42	2/20
Bicarbonate (SCHEMBL9058396)	0.42	2/20
SCHEMBL4960293	0.41	2/20
SCHEMBL4961968	0.40	2/20
SCHEMBL6686992	0.40	2/20
SCHEMBL9429122	0.38	2/20
Chloramphenicol (SCHEMBL10796001)	1.00	1/20
Geneticin (SCHEMBL15596)	0.93	1/20
Geneticin (SCHEMBL5006573)	0.93	1/20
Geneticin (SCHEMBL9920496)	0.93	1/20
Chloramphenicol (SCHEMBL16111)	0.90	1/20

Clinical trials — most relevant to RPS9 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes	PHASE4	UNKNOWN
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients	PHASE2	COMPLETED
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients	PHASE1/PHASE2	COMPLETED
Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety	PHASE2	COMPLETED
Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer	PHASE1/PHASE2	COMPLETED
Phase II Study of Simvastatin Plus Irinotecan, Fluorouracil, and Leucovorin(FOLFIRI) for Metastatic CRC	PHASE2	COMPLETED
Assessing the Safety, Tolerability, and Efficacy of APR-2020 in Pediatric and Adolescent Subjects With RPS19 Deficient Diamond-Blackfan Anemia	PHASE1	RECRUITING
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	PHASE1	WITHDRAWN
Mobilization of CD34+ Peripheral Blood Stem Cells in Patients With Diamond Blackfan Anemia Syndrome (DBAS)	nan	RECRUITING
Effect of Branched Chain Amino Acids on Muscle	nan	COMPLETED
Thymidylate Synthase Polymorphisms as a Predictor of Toxicity to 5-Fluorouracil Based Chemotherapy in Stage III Colon Cancer	nan	UNKNOWN
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Micro Ribosomal Nucleic Acid 155 in Non Hodgkin Lymphoma	nan	COMPLETED
Personalized Medicine Program on Myelodysplastic Syndromes: Characterization of the Patient's Genome for Clinical Decision Making and Systematic Collection of Real World Data to Improve Quality of Health Care	nan	COMPLETED
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
Identifying Genes and Mutations Underlying Retinitis Pigmentosa and Allied Diseases	nan	UNKNOWN
Natural History and Genetic Studies of Usher Syndrome	nan	COMPLETED
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy	nan	UNKNOWN
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Protein Intake and Step Reduction in Older Adults	nan	COMPLETED
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants.	nan	UNKNOWN
Prevalence of a Non-Expressing 11B Mutation in Aka Peoples of the Central African Republic	nan	COMPLETED
Aberrant Splicings Due to Microsatellite Instability in Colorectal Cancer : Physiopathological and Clinical Impact	nan	UNKNOWN
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia	nan	NOT_YET_RECRUITING
Stakeholders of Rare Diseases Informing Values In Neuroethics	nan	RECRUITING
miR-155 Expression in Episodic and Chronic Migraine	nan	UNKNOWN
Genetic Analysis of Gray Platelet Syndrome	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a RPS9 binder may also engage these)

Protein	Name	Similarity
A6QLG5	—	1.000	A6QLG5 →
Q6ZWN5	—	1.000	Q6ZWN5 →
P29314	—	1.000	P29314 →
A9L913	—	1.000	A9L913 →
B7NZS8	—	1.000	B7NZS8 →
B4PEU8	—	1.000	B4PEU8 →
P55935	—	1.000	P55935 →
P05755	—	1.000	P05755 →
P52810	—	1.000	P52810 →
Q09757	—	1.000	Q09757 →
Q20228	—	1.000	Q20228 →
Q9LXG1	—	0.999	Q9LXG1 →
O13516	—	0.999	O13516 →
A0A1D8PGY8	—	0.999	A0A1D8PGY8 →
Q9FLF0	—	0.999	Q9FLF0 →
P17959	—	0.999	P17959 →
O15612	—	0.997	O15612 →
O59675	—	0.997	O59675 →
Q25555	—	0.995	Q25555 →
P14132	—	0.994	P14132 →
Q8SRW6	—	0.993	Q8SRW6 →
O26142	—	0.993	O26142 →
A3CWH7	—	0.992	A3CWH7 →
A4YIN4	—	0.992	A4YIN4 →
A5UN53	—	0.992	A5UN53 →
B8GEG7	—	0.992	B8GEG7 →
Q46GC8	—	0.992	Q46GC8 →
Q97B95	—	0.991	Q97B95 →
A7IAH7	—	0.991	A7IAH7 →
B6YSQ1	—	0.991	B6YSQ1 →